To include your compound in the COVID-19 Resource Center, submit it here.

Vir’s aftermarket weakness adds to skittishness for IPO queue

Despite pricing within range, the anti-infective company lost value, compounding concerns for other biotechs

The tepid performances of two high-profile IPOs late in the week added to a widening body of evidence that investors’ demand for new biotech listings has begun to weaken, despite a long queue of companies hoping to get out this year.

Although Vir Biotechnology Inc. (NASDAQ:VIR) priced its IPO within its proposed range late Thursday, the company quickly lost 30% of its value in

Read the full 639 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers